plasma
therapi
consist
bring
patient
need
gener
suffer
sever
resist
current
therapi
even
lethal
infectionplasma
specif
fraction
antibodi
along
immunoglobulin
possibl
heal
factor
obtain
immun
blood
donor
donor
voluntari
benevol
either
activ
immun
individu
convalesc
person
plasma
therapi
use
sinc
spanish
flu
regularli
viral
epidem
threaten
vulner
popul
last
report
occurr
ebola
viru
outbreak
west
africa
precis
action
mechan
plasma
therapi
fulli
delin
may
function
beyond
purifi
neutral
antibodi
la
consist
en
lapport
un
patient
en
victim
dune
infect
au
traitement
en
cour
et
potentiel
de
plasma
ou
danticorp
mai
aussi
de
immunoglobulin
et
de
facteur
de
cicatris
dan
le
plasma
de
donneur
ce
donneur
et
volontair
peuvent
avoir
ou
il
ont
mai
il
sont
alor
convalesc
la
mise
en
oeuvr
la
grand
gripp
espagnol
de
pui
ensuit
chaqu
occurr
viral
la
en
date
de
ebola
apparu
en
afriqu
de
louest
le
daction
de
la
de
seul
anticorp
neutralis
sont
encor
non
though
less
directli
pasteur
franc
bordet
belgium
identifi
key
factor
complement
neutral
action
antibodi
principl
serotherapi
establish
shown
immun
diphtheria
tetanu
toxin
larg
reli
antibodi
present
blood
anim
intent
immun
nonleth
dose
toxin
could
transfer
anim
experienc
activ
infect
success
appli
human
suffer
notabl
diphtheria
sera
divers
anim
speci
goat
hors
sheep
subject
flourish
pharmaindustri
immun
sera
save
numer
live
otherwis
lethal
effect
bacteri
toxin
though
expens
occasion
iatrogen
hazard
term
particular
serum
sick
actual
type
iii
hypersensit
immun
respons
accord
gell
coomb
classif
plasma
fraction
plasma
derivedtherapeut
factor
made
avail
around
immunoglobulin
ig
purifi
concentr
highli
immun
donor
fulli
recov
past
clinic
asymptomat
infect
constitut
socal
hyperimmun
immunoglobulin
fraction
human
igsand
particularli
specif
ig
non
onlyprogress
replac
use
anim
sera
especi
form
intraven
ig
ivig
still
current
use
notabl
neutral
tetanu
toxoid
toxin
hepat
b
viru
hbv
rubella
viru
pertussi
toxin
rabi
viru
besid
accumul
evid
polyclon
ig
plasma
offer
regular
blood
donorsund
form
ivigsconf
degre
protect
achiev
pathogen
elimin
reduct
patholog
sever
infect
patient
present
bacteri
sepsi
acut
viral
infect
ivig
use
even
propos
help
protect
expos
patient
especi
children
yet
develop
infect
human
immunodefici
viru
type
import
note
regular
basi
year
whole
blood
plasma
recov
convalesc
patient
transfer
activ
infect
individu
often
last
chanc
experiment
treatment
transfus
blood
purpos
confer
protect
current
practic
half
xxth
centuri
perform
experiment
protocol
often
intend
compassion
inde
decad
immunotherapi
allergen
hay
fever
initi
mari
loveless
demonstr
blood
immun
ragwe
sensit
individu
benefit
nonimmun
ragwe
sensit
individu
hay
fever
season
experi
tell
number
import
inform
protect
certain
sever
infect
diseas
transfer
serum
plasma
igsantibodi
ab
bulk
highli
purifi
protect
ab
obtain
process
deliber
infect
anim
host
naturallyinfect
convalesc
human
protect
ab
even
use
prophylact
specif
neutral
ab
also
polyreact
ig
confer
degre
protect
infect
diseas
past
present
centuri
experienc
number
viral
outbreak
evolv
epidem
along
viral
endemicepidem
situat
recent
effect
antivir
therapi
either
experiment
hazard
unafford
prove
exceedingli
lethal
threaten
global
health
system
call
protect
measur
nonexpos
popul
prophylaxi
expos
yet
infect
popul
experiment
therapi
attack
individu
situationsinclud
earli
spanish
flupropos
use
convalesc
plasma
therapi
besid
viral
infect
present
form
local
region
restrict
epidem
larg
attack
rate
within
expos
popul
low
expans
capac
epidem
particularli
sever
gener
often
lethal
viral
hemorrhag
fever
vhf
hantaviru
infect
found
elig
convalesc
plasma
therapi
protocol
whenev
possibl
lassa
fever
argentin
hemorrhag
fever
rift
valley
fever
sin
nombr
puumala
viru
infect
cite
besid
also
viral
infect
evolv
endemicepidem
emerg
reemerg
situat
major
killer
especi
lowincom
area
measl
hivaid
rabi
also
found
elig
plasma
therapi
late
viral
infect
particularli
lethal
compar
previous
cite
one
threaten
still
threaten
popul
develop
econom
develop
world
efficaci
antivir
chemotherapi
limit
test
opportun
use
specif
ivig
chikungunya
viru
infect
dengu
viru
infect
possibl
other
hepat
e
viru
hev
infect
also
trypanosoma
cruzi
infect
chaga
diseas
note
despit
experiment
attempt
plasmodium
falciparum
malaria
seem
resist
plasma
therapi
specif
ig
benefit
histor
sinc
roux
yersin
discov
clinic
diphtheria
symptomatolog
attribut
toxin
behr
shibasaburo
made
antidiphtheria
toxin
serum
avail
therapi
base
hyperimmun
sera
consist
use
treat
infect
individu
larg
appli
sulfonamid
introduc
year
one
largest
use
perhap
treat
tetanu
toxoid
anim
sera
thena
specif
human
ig
two
situat
still
reli
serum
anim
botul
diphtheria
cmv
infect
hepat
viru
hav
infect
measl
hepat
b
rabi
tetanu
pertussi
vaccinia
chickenpox
varicella
fought
human
sera
inde
plasma
fraction
made
avail
back
year
sinc
specif
ig
made
avail
convalesc
blood
individu
elig
blood
plasma
donat
hav
epidem
treat
back
unfraction
ig
treatment
specificfraction
igswer
use
treat
hav
hbv
infect
prior
largescal
campaign
vaccin
less
specif
prophylact
ivig
treatment
propos
treat
victim
toxic
shock
syndrom
ingest
contamin
food
base
evid
obtain
success
use
either
nonfraction
specif
ig
viral
infect
immun
therapi
given
occasion
fight
smallpox
outbreak
india
mani
occas
still
propos
ebola
crisi
fascin
reportactu
metaanalysi
former
report
contribut
physician
face
spanish
flu
patientsoff
lookback
serum
therapi
whole
blood
therapi
carri
varieti
practition
differ
countri
gener
observ
either
mild
distinct
improv
procedur
probabl
pioneer
experi
plasmaactu
serumtherapi
perform
face
viral
outbreak
mani
other
protect
measl
reli
long
time
plasma
therapi
viral
infect
offer
one
largest
report
experi
stillor
reboundinterest
recent
analyz
metaanalysi
cochran
seri
argentin
junin
viru
junv
bolivian
machupo
viru
macv
hf
describ
lassa
viru
lasv
earli
lead
sever
hemorrhag
prove
benefit
convalesc
plasma
therapi
protocol
prior
new
antivir
drug
use
sever
public
report
particular
experi
plasma
therapi
lasv
infect
two
import
observ
made
avail
time
firstli
latea
oppos
earlyplasma
confer
protect
diseas
secondli
plasma
bring
heal
factor
prevent
excess
vascular
leakag
also
procoagul
factor
coupl
publish
experi
plasma
therapi
rift
valley
fever
viru
rffv
sin
nombr
viru
snv
latter
case
patient
recov
anoth
hantaviru
ie
cardiopulmonari
syndrom
hcp
hantaviru
clear
viral
load
exposur
snv
recov
success
specif
ig
obtain
convalesc
individu
show
promis
experiment
protect
monkey
infect
puumala
viru
puuv
next
interest
explor
immunotherapi
crimeancongo
hf
viru
anoth
member
bunyavirida
famili
belong
nairoviru
genu
sever
group
side
atlant
attempt
infus
heat
plasma
collect
seroposit
symptomless
individu
aid
patient
french
group
led
jeanjacqu
inde
pioneer
compassion
protocol
outcom
mainten
week
ab
transfus
patient
delay
appear
aid
symptom
inform
made
avail
investig
probabl
factor
ab
matter
benefici
observ
effect
human
sarscov
outbreak
rapidli
face
convalesc
therapi
initi
report
made
avail
quit
earli
episod
releas
public
claim
therapi
follow
drop
viral
load
improv
patient
symptom
metaanalysi
conduct
quit
recent
conclud
safeti
procedur
global
decreas
mortal
lookback
studi
elegantli
provid
addit
inform
compar
antivir
therapi
thatfor
themprov
harm
blame
pose
convalesc
plasma
therapi
perform
mean
either
unfraction
plasma
purifi
ig
anoth
analysi
report
interest
therapi
mention
sustain
antiinflammatori
effect
carri
lookback
studi
metaanalys
also
driven
perspect
offer
convalesc
plasma
therapi
treat
individu
infect
merscov
epidem
affect
present
arab
peninsula
earli
year
xxist
centuri
alreadi
face
two
seriou
flu
epidem
new
influenzaviru
serotyp
infect
still
ongo
countri
egypt
led
occasion
convalesc
plasma
therapi
initi
prepared
plan
interrog
possibl
propos
plasma
therapi
futur
serotyp
would
becom
pandem
flu
infect
led
sever
case
plasma
therapi
hyperimmun
ig
therapi
propos
studi
report
metaanalys
lookback
studi
show
certain
efficaci
appli
earli
day
exposur
experiment
studi
done
materi
collect
outbreak
also
conclud
procedur
show
promis
reduc
viral
burden
morbiditymort
outbreak
due
chikungunya
viru
chikv
member
togavirida
famili
genu
alphaviru
observ
indian
ocean
mayott
island
one
third
popul
infect
larg
number
symptomat
sever
symptomat
viru
spread
india
caribbean
area
also
present
southern
europ
attack
rate
econom
societ
impact
use
purifi
specif
igg
taken
consider
specif
ivig
obtain
plasma
convalesc
island
use
year
children
suffer
infect
french
caribbean
island
data
made
avail
scientif
commun
far
strong
hope
therapi
proof
concept
convalesc
plasma
effici
ebolaviru
ebv
diseas
brought
soon
experiment
model
intens
outbreak
westcentr
africa
prompt
ngo
divers
consortia
us
europ
set
protocol
collect
plasma
convalesc
individu
despit
uncertainti
one
hand
viral
clearanc
hand
exist
sustain
protect
neutral
ab
gener
prefer
made
fraction
ig
process
plasma
given
repeat
apheresi
procedur
altern
practition
insist
interest
therapeut
specif
plasma
bring
endotheli
heal
plasma
procoagul
factor
plan
made
ivig
supposedli
prepar
order
use
new
case
declar
one
studi
report
use
convalesc
plasma
addit
antivir
drug
two
patient
recov
without
notic
sequel
although
one
experienc
multiorgan
failur
necessit
kidney
replac
author
inde
conclud
role
convalesc
plasma
vs
support
care
difficult
delin
plasma
therapi
last
chanc
treatmenta
compassion
therapyor
subtl
resuscit
tool
care
cure
sever
infect
patient
show
organ
failur
distress
often
sever
hemorrhag
hundr
year
practic
allow
precis
answer
question
howev
one
constant
observ
plasma
therapi
hyperimmun
ig
therapi
must
appli
earli
possibl
onset
infect
andor
diseas
manifest
regard
possibl
mode
action
therapi
technologist
tend
favor
specif
ig
crack
plasma
wherea
physiologist
recogn
addit
effect
heal
factor
prevent
excess
vascular
leakag
procoagul
antifibrinolyt
factor
direct
potenti
interest
obvious
infecti
diseas
present
hf
better
counteract
purifi
ab
manufactur
monoclon
ab
inde
strongli
wish
case
exampl
hiv
mani
attempt
made
coupl
decad
anoth
viru
display
high
attack
rate
lead
sever
patholog
includ
hf
symptom
seen
denv
could
theori
elig
plasma
ig
therapi
howev
viral
infect
versatil
elicit
neutral
ab
propos
ab
rais
one
serotyp
may
even
facilit
toward
three
serotyp
program
howev
aim
elicit
modifi
ab
protect
denv
inde
consid
seriou
threat
certain
part
world
potenti
reach
milder
temper
area
south
europ
final
remark
import
note
plasma
therapywhatev
form
convalesc
plasma
purifi
ab
possibl
generos
patient
either
recov
infect
expos
without
manifest
symptom
proven
absenc
viru
persist
case
benevol
mani
us
would
pledg
human
qualiti
alter
money
busi
system
stay
field
voluntari
nonremuner
system
blood
donat
obvious
one
make
sure
plasma
purifi
igsab
devoid
remain
viru
pathogen
protocol
use
pathogen
reduct
technolog
larg
avail
econom
wealthi
countri
must
made
avail
well
develop
countri
face
viral
outbreak
case
ebola
crisi
author
declar
compet
interest
